To the editor: Identification of biomarkers for response to novel therapeutic agents is an essential step for the success of tailored treatments in cancer. Preliminary data from clinical trials indicate that inhibitors of the spleen tyrosine kinase (SYK) may be efficacious in subsets of diffuse
No takes yet. Share an insight, caveat, or question.
McKeller et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: